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More than 342,000 people with dementia are living in Australia – around 
70% of whom live in the community.1 
Whilst dementia can occur in younger 
people, the prevalence of dementia 
increases markedly with age; around 
9% of Australians aged 65 years and 
over have dementia, increasing to 
30% of people aged 85 years or more.1 
As the majority of people living with 
dementia are elderly, many have 
multiple comorbidities that also require 
management. In a recent international 
study involving people with dementia 
living in the community, dementia was 
the sole chronic medical condition in 
less than 13% of participants.2 
Approximately half of all Australians aged 
between 65–74 years have five or more 
chronic medical conditions, increasing 
to 70% of those aged 85 and older.3 
Consequently, the older a person is the 
more likely they are to take multiple 
medications, with around half of the 
population aged 65 years or more 
taking five or more regular medications.4 
People living in residential aged care 
facilities (RACFs), over half of whom have 
dementia,5 take on average between nine 
and ten regular medications.6,7
As a consequence of this high 
prevalence of chronic disease and 
medication use, pharmacists can have 
an important role in supporting people 
living with dementia and their carers 
throughout their journey with dementia. 
This ranges from ensuring that the 
community pharmacy environment is 
responsive to the needs of people with 
dementia, through to a comprehensive 




As the majority of people with 
dementia live in the community, there 
is an increasing awareness of the 
need to ensure that communities are 
appropriately equipped to support people 
living with dementia.8 This is termed being 
dementia-friendly. A core component 
of dementia-friendly communities 
involves businesses being responsive 
to the additional needs of people with 
dementia. As people with dementia may 
experience symptoms such as memory 
loss or confusion that can make business 
interactions more difficult,8 it can be 
particularly beneficial for businesses to 
become dementia-friendly. 
Whilst the characteristics of individual 
dementia-friendly businesses differ 
depending upon the business type and 
services provided, all share a number of 
common principles8:
•	 awareness of the needs of people 
with dementia
•	 commitment from all staff to being 
dementia friendly
•	 adequate staff knowledge and 
understanding about dementia
•	 appropriate physical environment
•	 simplified documentation and 
processes where possible
•	 ongoing review and improvement. 
For community pharmacies, this may 
involve a number of activities, such as:
•	 consulting with local people with 
dementia and their carers to identify 
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LeArning objectives
After reading this article, pharmacists should be 
able to:
•	 Identify of the role of the pharmacist in helping 
people following a diagnosis of dementia
•	 Understand how to support customers living 
with dementia
•	 Understand issues associated with medication 
use in dementia
•	 Recognise the benefits of medication reviews for 
people living with dementia.
Competency standards (2010) addressed: 1.3, 6.1, 
6.2, 6.3.
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their specific needs in community 
pharmacies
•	 staff training in strategies for 
communicating with people with 
dementia
•	 assessing the physical pharmacy 
environment for adequate signage, 
lighting and contrast 
•	 reviewing the dispensing process for 
customers who are known to have 
dementia to minimise opportunities for 
confusion (e.g. prescription reminders,9 
organising scripts, simplifying 
paperwork if possible).
Alzheimer’s Australia recently released 
a toolkit for businesses (https://
fightdementia.org.au/about-us/dementia-
friendly-communities/toolkits) to 
enable them to improve their dementia-
friendliness, and be recognised for it.10 The 
toolkit provides guidance for businesses 
to create an action plan to become 
more dementia-friendly, based on the 
aforementioned principles. 
Medication management and 
dementia
The role of pharmacists in supporting 
people living with dementia is not limited 
to the physical pharmacy environment, 
and there are evolving opportunities 
for pharmacists to optimise medication 
management for people with dementia. 
The high prevalence of multiple chronic 
diseases and polypharmacy in older 
people is associated with a high risk of 
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medication misadventure. For people 
with dementia, the use of medications 
presents some unique challenges, and it 
has been suggested that they are amongst 
the most vulnerable to adverse outcomes 
associated with inappropriate medication 
management.11 Furthermore, people 
with dementia often require complex 
medication regimens that can change 
frequently, particularly when transitioning 
between care sites. Consequently, effective 
medication management is vital in ensuring 
that people with dementia receive the 
greatest benefit from medication use 
whilst the risk of medication-related harm 
is minimised. Pharmacists therefore have 
an important role in optimising medication 
management for people with dementia, 
ranging from assisting with adherence to 
medication reviews. 
Medication adherence 
dementia is associated with particular 
low adherence rates, with over 30% 
of people with dementia reported to 
not take their medications as intended 
in some studies.12,13 There are many 
ways by which pharmacists may assist 
people with dementia and their carers 
to improve compliance, and the most 
effective strategies typically involve an 
individualised, multi-faceted approach. 
examples of some interventions that have 
been found to assist with compliance are 
listed in Table 1.
Table 1. Measures (single components) for 
helping people with dementia take their 




verbal, written and 
visual material
•	Dose administration 





scheduled delivery of 
medications
•	Involving patients 
and carers more in 




















Adapted from Arlt, et al.13
Pharmacists may find the MedsCheck 
Service particularly valuable for identifying 
and addressing many of the issues that 
home-dwelling people with dementia 
and their carers may be experiencing with 
medication management.14
clinical roles 
Managing symptoms of dementia
In addition to assisting with adherence, 
pharmacists can play a significant role 
in supporting people with dementia 
through various clinically-focused 
services. As discussed previously, 
dementia frequently co-exists with other 
chronic diseases; hence, people with 
dementia use medications to manage 
both the symptoms of dementia and 
non-dementia conditions. 
The syndrome of dementia 
is characterised by cognitive 
symptoms, such as memory loss, 
and behavioural and psychological 
symptoms of dementia (BPSd; e.g. 
aggression, agitation, hallucinations, 
walking without purpose and sexual 
disinhibition).15 Almost all people 
with dementia experience BPSd 
at some point, which can seriously 
impact upon their quality of life and 
that of their carers.15 Managing BPSd 
can be complex as several symptoms 
can occur concurrently, and many 
symptoms frequently respond poorly 
to pharmacological treatment, if at 
all. Antipsychotics have been used for 
many years to treat BPSd, and some, 
particularly risperidone, have been 
found to reduce some BPSd in up to 
20% of people, particularly aggression.16 
However, antipsychotics are ineffective 
for BPSd in many people, and there is 
growing concern in many countries that 
the use of these drugs may not always 
be consistent with best practice.15-17 It 
should also be noted that risperidone 
is currently the only antipsychotic 
TGA-approved and PBS-subsidised for 
treatment of BPSd, with a streamlined 
authority requiring that it be prescribed 
only after non-pharmacological 
approaches to management of 
symptoms have proven unsuccessful.
In Australian RACFs, between 20–25% 
of residents take an antipsychotic 
medication. A number of authors have 
suggested that many people with 
dementia may be taking antipsychotics 
needlessly, exposing them to an 
increased risk of severe adverse effects 
including cerebrovascular events and 
death.16,18,19 An analysis of the use of 
atypical antipsychotics for the treatment 
of BPSd in 1,000 people with dementia 
for approximately 12 weeks results in 
clinically significant improvements in 
BPSd for between 91–200 people, with 
18 additional cerebrovascular events and 
10 additional deaths.20 This is in addition 
to other more overt adverse effects 
including extrapyramidal symptoms, 
sedation, and gait disturbances.15
As a consequence of the limited 
efficacy and risk of harm associated 
with antipsychotic use, clinical 
BPSd guidelines recommend non-
pharmacological strategies as first-
line treatment.16 If an antipsychotic is 
required, then its use should be limited 
to severe symptoms of agitation, 
aggression and psychosis, at the lowest 
effective dose for the shortest possible 
time.16 However, there is evidence 
that a high proportion of people with 
dementia who are commenced on 
antipsychotics continue to take them 
for extended periods; in one Australian 
study 60% of RACF residents were taking 
the same antipsychotic at the same 
dose 12 months after an initial audit.17 
This is despite good evidence that the 
withdrawal of antipsychotics does not 
worsen symptoms in 70% of people.16 
As antipsychotics are ineffective for 
BPSd in many people, a number 
of other pharmacological agents 
have been used for management, 
including cholinesterase inhibitors, 
antidepressants, memantine, 
anticonvulsants and benzodiazepines.15 
of these, benzodiazepines are perhaps 
the most widely used, particularly for 
anxiety, agitation and insomnia.21 despite 
benzodiazepines being most effective 
and least likely to cause adverse effects 
when used for short periods at low doses, 
there is evidence that many people 
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with dementia take them for much 
longer periods than recommended.17 
Consequently, they are at risk of a range 
of adverse effects including excessive 
sedation, ataxia, amnesia and confusion 
which can be particularly problematic 
in people who are already experiencing 
significant cognitive impairment 
associated with their dementia.21
A number of studies have demonstrated 
that pharmacists can optimise the 
appropriateness of antipsychotic and 
benzodiazepine use for BPSd in people 
with dementia.22,23 A trial undertaken 
in RACFs in Tasmania involving a series 
of pharmacist-led strategies involving 
medications audits and staff education 
sessions significantly reduced the 
proportion of residents regularly taking 
antipsychotics and benzodiazepines.23 
Based on these results, this program 
is currently being rolled out Australia-
wide. For pharmacies that provide 
Webster-paks to RACFs, software has 
been developed for pharmacies to 
report antipsychotic usage rates for each 
facility.24 The reports facilitate analysis 
and management of antipsychotic use 
in RACFs, with the intention of ensuring 
appropriate use of these medications. 
Medications that may worsen dementia
Pharmacists also have an important 
role in identifying and resolving drug-
related problems involving medications 
that may exacerbate the symptoms 
of dementia. of particular note are 
medications with anticholinergic 
activity; many forms of dementia are 
associated with a loss of cholinergic 
neurones, and medications with 
central anticholinergic action can 
further reduce cholinergic function 
and impair cognition. numerous 
commonly prescribed medications 
possess anticholinergic properties, 
including selected anti-emetics, 
antispasmodics, bronchodilators, 
anti-arrhythmics, antihistamines, 
analgesics, antihypertensive agents, 
antiParkinsonian agents, skeletal muscle 
relaxants, acid-suppressive drugs and 
psychotropics.25 A recent international 
study identified that the use of these 
agents, particularly in combination 
with other sedatives, was associated 
with a significantly increased risk of 
hospitalisation and death in people with 
Alzheimer’s disease.26 
Several studies have found that 
medication reviews by pharmacists 
can reduce people’s exposure to 
medications with anticholinergic and 
sedative effects.27,28 An Australian study 
of Home Medicines Reviews (HMRs) 
reported an absolute 15% decrease 
in the use of these medications in 
people who received the service (60.5% 
of participants down to 51.6%).28 A 
similar study of Residential Medication 
Management Reviews (RMMRs) identified 
that residents’ total anticholinergic and 
sedative burden decreased by a mean of 
12% from baseline following the RMMR.29 
Consequently, it may be considered that 
HMRs and RMMRs have the potential to 
be of substantial benefit for people living 
with dementia to minimise the use of 
medications that may adversely affect 
their cognitive function. Pharmacists 
practicing in tertiary settings are also well 
placed to identify and minimise the use 
of these medications where possible. 
Dementia as a criteria for HMR and 
RMMR referral
The potential benefits of HMRs and 
RMMRs for people with dementia have 
been recognised since the inception of 
these services. People with dementia 
frequently fulfil a number of the 
criteria suggested to identify a person 
likely to benefit most from a HMR. 
In particular, one criterion identifies 
people ‘managing their own medicines 
because of… confusion/dementia or other 
cognitive difficulties’ as likely to benefit 
from HMRs.30 The current HMR program 
guidelines maintain reference to ‘altered 
cognitive function’ as a potential reason 
for repeated provision of the service.31 
Similarly, current RMMR guidelines 
include a ‘change in medical condition or 
abilities (including… cognition…)’ as a 
possible trigger for a RMMR.32
dementia is a chronic, terminal 
condition, and comfort is the primary 
goal of care stated by the majority of 
proxies of RACF residents with advanced 
dementia.33 However, there is evidence 
that many people with advanced 
dementia continue to receive medications 
that are unlikely to achieve this aim, with 
a recent study undertaken in the USA 
reporting that 54% of RACF residents 
with advanced dementia received at 
least one medication of questionable 
benefit.34 As the aim of RMMRs is to 
optimise the benefits from medicine use 
and enhance quality of life,35 RMMRs may 
be particularly beneficial in ensuring that 
people with advanced dementia only 
receive medications that are aligned to 
their goals of care.
conclusion
Medicine use is frequently problematic 
for people living with dementia and their 
carers. Pharmacists can support people 
living with dementia in a number of 
ways, including promoting dementia-
friendly pharmacy design, assistance with 
medication management and providing 
clinical services to minimise drug-related 
problems. Pharmacists can support people 
living with dementia across all sites of 
healthcare delivery, and are funded to 
provide a range of services that have been 
shown to improve health outcomes for 
these people. 
As the number of people living with 
dementia increases over the coming years, 
there is an opportunity for pharmacists 
to be at the forefront of professional 
healthcare support for these people and 
their carers throughout their journey with 
dementia. 
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1. Which ONE of the following 
statements regarding dementia is 
the LEAST appropriate? 
a) Dementia may occur in people less than 
65 years of age.
b) The prevalence of dementia is 
increasing in Australia.
c) The majority of Australians with dementia 
live in residential aged care facilities.
d) Polypharmacy is common in people 
with dementia.
2. Which ONE of the following is LEAST 
likely to be considered a characteristic 
of a dementia-friendly pharmacy?
a) Training of a single staff ‘champion’ in 
communication techniques for people 
with dementia.
b) Streamlined processes and simplified 
documentation wherever possible. 
c) Ongoing evaluation of all strategies 
implemented to improve dementia-
friendliness.
d) Environmental audit of signage, 
lighting and colour contrast to ensure 
appropriateness for people with dementia.
3. Which ONE of the following 
statements regarding medication 
use in people with dementia is the 
MOST appropriate?
a) Most adherence issues can be resolved 
with only the introduction of a dose 
administration aid (DAA).
b) Transitions between care sites are 
a particularly high risk period for 
medication misadventure.
c) Non-adherence is rarely an issue for 
people with dementia. 
d) People with dementia are generally at no 
greater risk of medication misadventure 
than the greater population.
4. Which ONE of the following 
statements regarding sedative use 
for the management of behavioural 
and psychological symptoms of 
dementia (BPSD) is the LEAST 
appropriate?
a) There is evidence that many people 
with dementia are prescribed 
benzodiazepines for much longer 
periods than guidelines recommend.
b) When used for BPSD, antipsychotics 
are associated with an increased risk of 
cerebrovascular accidents and death.
c) Antipsychotics will improve most BPSD 
for a majority of people with dementia if 
given for a sufficient length of time.
d) Educational interventions delivered by 
pharmacists to RACF staff have been 
found to significantly reduce sedative 
use for BPSD.
5. As the manager of a community 
pharmacy, you decide that the 
business should work towards 
becoming more dementia-friendly 
and increase its services to support 
people living with dementia. You 
create an action plan based on 
the Alzheimer’s Australia business 
toolkit, and start promoting a range 
of adherence assistance strategies, 
MedsChecks and clinical medication 
management reviews (HMRs and 
RMMRs). However, a local GP asks a 
number of questions about the need 
for these services and whether there 
is any evidence that pharmacists can 
support people living with dementia. 
Which ONE of the following 
responses is the LEAST appropriate?
a) Whilst there is evidence that most 
medications of questionable benefit are 
ceased in advanced dementia, RMMRs 
improve adherence with remaining 
medications.
b) HMRs have been shown to significantly 
reduce the burden of medications with 
anticholinergic and sedative effects in 
people who receive the service. 
c) MedsChecks provide an ideal 
opportunity to identify and address 
medication management issues 
that people with dementia may be 
experiencing.  
d) Current RMMR guidelines specifically 
reference people with altered cognitive 
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